The Lancet Microbe (Apr 2022)

Multiplexed rapid technologies for sexually transmitted infections: a systematic review

  • Angela Karellis, PhD,
  • Faheel Naeem, MPH,
  • Suma Nair, ProfMD,
  • Sneha D Mallya, MD,
  • Jean-Pierre Routy, MD,
  • Jacqueline Gahagan, ProfPhD,
  • Cédric P Yansouni, MD,
  • John Kim, PhD,
  • Nitika Pant Pai, PhD

Journal volume & issue
Vol. 3, no. 4
pp. e303 – e315

Abstract

Read online

Summary: Multiplexed technologies for sexually transmitted infections offer a convenient diagnostics option to screen, confirm, and treat multiple pathogens simultaneously. Due to scarce published real-world diagnostic performance data, we did a systematic review. Two reviewers searched major databases for data published between Jan 1, 2009, and April 20, 2020, and abstracted and analysed sensitivity and specificity data from 24 studies, which assessed 17 multiplex rapid nucleic acid amplification test platforms and seven multiplex immunochromatographic devices. Overall, these studies evaluated 19 sexually transmitted infections in 26 126 individuals. High sensitivity and specificity were shown for rapid nucleic acid amplification platform tests and immunochromatographic devices, with performance varying by pathogen, device, seropositivity, and subpopulation screened. As most devices yielded more than 95% sensitivity and specificity, immunochromatographic tests and rapid nucleic acid amplification test platforms can be advised for screening and confirmatory use. These highly accurate devices are appropriate for integrated, rapid screening initiatives for sexually transmitted infections to screen and treat many of these infections simultaneously, for antimicrobial stewardship, and for disease elimination programmes.